论文部分内容阅读
目的:观察益气复元汤对大肠癌患者术后化疗减毒增效的临床作用。方法:对照组25例,使用FOLFOX4方案化疗。治疗组24例,除FOLFOX4方案化疗外加用益气复元汤,于化疗前3天开始服用至化疗后2天,分别就体重,不良反应、免疫功能、KPS评分等方面进行观察。结果:治疗组化疗后体重、KPS评分稳定情况优于对照组,具有统计学差异,P<0.05;不良反应方面治疗组在白细胞、血小板减少及恶心呕吐、腹泻及ALT升高等方面明显优于对照组,P<0.01;在红细胞减少及胆红素、ALP,AST,Cr、BUN升高、神经毒性方面两组之间无显著性差异(P>0.05);化疗后两组CD 4+、CD 8+、CD 4+/CD 8+、NK水平均下降,但治疗组CD 4+、CD 4+/CD 8+、NK水平高于对照组,有统计学意义,P<0.01。结论:益气复元汤对大肠癌患者术后化疗具有减毒增效的临床作用。
Objective: To observe the clinical effect of Yiqi Fuyuan Decoction on attenuated and synergistic effect of chemotherapy in patients with colorectal cancer. Methods: The control group of 25 cases, the use of FOLFOX4 chemotherapy. In the treatment group, 24 cases were treated with FQFXX4 plus chemotherapy with Yiqi Fuyuan Decoction. The treatment was started 3 days before chemotherapy to 2 days after chemotherapy. Body weight, adverse reactions, immune function and KPS score were observed respectively. Results: After treatment, the stability of KPS score in treatment group was better than that in control group (P <0.05). Adverse reactions in treatment group were significantly better than those in control group in leukopenia, thrombocytopenia, nausea and vomiting, diarrhea and ALT Group (P <0.01). There was no significant difference between the two groups in erythrocyte reduction, bilirubin, ALP, AST, Cr, BUN elevation and neurotoxicity 8 +, CD 4 + / CD 8 + and NK decreased, but the levels of CD 4 +, CD 4 + / CD 8 + and NK in the treatment group were higher than those in the control group, with statistical significance (P <0.01). Conclusion: Yiqi Fuyuan Decoction has the clinical effect of reducing the toxicity and increasing the efficiency of chemotherapy in patients with colorectal cancer.